BSN Medical Launches Multiple Products and New Therapeutic Solutions at SAWC Spring

BSN Medical Launches Multiple Products and New Therapeutic Solutions at SAWC Spring

BSN medical Launches Multiple Products and New Therapeutic Solutions at SAWC Spring

Focus on VLUs, DFUs and Post-Op Management for Faster Healing

CHARLOTTE, N.C., April 15, 2016 – BSN medical, the global integrated medical therapy provider, announced today the launch of three new integrated therapeutic solutions focused on treating venous leg ulcers (VLUs), diabetic foot ulcers (DFUs) and postoperative surgical sites. In addition, these solutions are supported with the launch of two new wound care products, plus products featuring the company’s DACC Technology, a powerful alternative to silver antimicrobial dressings, and the JOBST® brand of compression therapy.

BSN’s suite of new wound care solutions is being showcased in booth #601 at the Symposium on Advanced Wound Care (SAWC Spring) in Atlanta.

“By focusing on integrated therapeutic solutions, versus only on products, all aspects of wound care can be taken into consideration to enable an optimal environment for wound healing,” said Todd Healy, president of North America for BSN medical. “Our vision is not only to provide solutions to the care provider, but also to improve the patient experience. BSN is one of the few wound care companies that can offer a broad portfolio of products while also providing comprehensive solutions that meet the needs of patients and their individual wound care.”

The new VLU integrated therapeutic solution features a process of removing exudate and bacteria, rebuilding tissue, reducing edema and preventing recurrence of chronic wounds. BSN’s DACC Technology, for infection management, removes harmful and damaging bacteria. The new Cutimed® Epiona, a native collagen, helps to rebuild tissue. The JOBST Compression Therapy line of bandages and wraps reduce edema, and the JOBST graduated compression legwear prevent recurrence as needed.

Cutimed Epiona is an absorbent wound dressing developed with the same microstructure as the intact collagen network of human skin, thereby helping to rebuild damaged tissue. The open, porous 3D Matrix structure allows the dressing to support the capture and binding of excessive proteases (enzyme that breaks down proteins) and inflammation-inducing elements (MMPs), to help protect the growth factors that stimulate healing. It also delivers structural support for proliferation of vital cells needed for wound repair, and creates an ECM-like scaffold that encourages cell proliferation and tissue growth.

With a focus on Cutimed Epiona, the company announced that three accepted clinical posters highlighting the healing effectiveness of the product as part of an overall wound care solution, as well as an industry-sponsored, educational breakfast symposium, are part of the SAWC 2016 program.

One poster entitled, “A Multi-Center Clinical Study Evaluating the Effectiveness of Native Collagen Calcium Alginate Dressing in Chronic Non-Healing Wounds,” by Thomas Serena, M.D., et al., highlights fast, effective healing using a native collagen dressing.

A second poster entitled, “Treatment Of Chronic Venous Leg Ulcers Using Integrated Therapies: DACC Technology, A New Bioactive Native Collagen Featuring 3D Matrix Technology, And A New 2-Layer Compression Bandage System,” by Kazu Suzuki, DPM, CWS, describes the use of an integrated therapy solution for the management and prevention of Venous Leg Ulcers. Products with DACC Technology were used for infection management, the Cutimed Epiona to help rebuild tissue, and JOBST Compression Therapy for edema reduction, were all part of the standard of care provided.

Finally, a third poster entitled, “The Use of a New Collagen Alginate Dressing in the Management of Chronic Wounds: A Case Series,” by James B McGuire, DPM, PT, et al., provides practical use case examples using Cutimed Epiona in the treatment and management of diabetic foot ulcers.

BSN’s interactive educational breakfast session, a CME, CNE, CPME accredited meeting, will study integrated therapeutic solutions for the treatment of venous leg ulcers. The complimentary industry-supported symposium will take place on Friday, April 15, from 7:30 – 9:00 a.m., in the Georgia World Congress Center.

BSN medical is also focusing on postoperative surgical site infections and will showcase the Leukomed® Post-op range of dressings including Leukomed Control at the SAWC Spring symposium. The dressing provides ideal healing conditions by creating an optimal moisture level in the wound and adapting to the skin’s elasticity. Because of its clarity, the dressing puts the clinician in control of the healing process and makes early detection of the wound possible without lifting or changing the dressing.

About BSN medical

BSN medical is a global leader in wound care & related vascular diseases, lymphology and non-invasive orthopedic products. Founded in 2001, the company currently employs approximately 6,100 members of staff and generated revenues of € 861 m in 2015. The company aims to provide an integrated therapy-driven approach – grounded in a broad portfolio of products, enhanced by insights into current therapeutic areas and complemented by a progressive approach to partnerships. Its well-known brands such as Leukoplast®, Cutimed®, JOBST®, Delta Cast®, Delta Lite® and Actimove® are among the most trusted in healthcare. With its comprehensive product portfolio, BSN medical addresses patients’ needs in the most prevalent conditions in wound care and vascular diseases and orthopedic treatments.

More information:

# # #

Media Contact:

Amy Cook

925.552.7893

Media Contact Europe:

Friederike Herrfurth

+352.621.531.674

1